Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 163

  • 3 901 clinical trials
  • 1 548 recruiting
  • 705 conditions
  • 31 countries

Conditions in this area

705 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma165Neoplasm158Acute myeloid leukaemia132Neoplasm malignant128Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+681

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 901 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 901 clinical trials

Skin squamous cell carcinoma metastatic+1

Not yet recruiting

Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Neoplasm malignant

Not yet recruiting

Study of BLU-451 for Patients with Advanced Cancers Having EGFR Exon20 Insertion Mutations

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BLU-451
  • Sponsor:Blueprint Medicines Corp.

Squamous cell carcinoma of head and neck

Not yet recruiting

Study on Sodium Thiosulfate to Prevent Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Thiosulfate
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Neuroblastoma

Not yet recruiting

Study of ABTL0812 with Irinotecan and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium 2-HYDROXYLINOLEATE
  • Sponsor:Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Glioblastoma

Not yet recruiting

Study of NMS-03305293 and Temozolomide for Adults with Recurrent Glioblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:NMS-03305293
  • Sponsor:Nerviano Medical Sciences S.r.l.

Acute myeloid leukaemia

Not yet recruiting

Study of Dasatinib for Patients with Acute Myeloid Leukemia Not Responding to Venetoclax-Azacitidine Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Institut Paoli-Calmettes

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Plasma cell myeloma

Not yet recruiting

Study on Alnuctamab and Mezigdomide for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Hormone receptor positive breast cancer

Not yet recruiting

Study on Cannabidiol for Joint Pain in Early Breast Cancer Patients on Hormone Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Institut Gustave Roussy

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab463 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.